Saroglitazar

Name: Saroglitazar in Primary biliary cholangitis: Dosage forms and strengths
Published: 2026-09-14T15:39:06-04:00

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Dosage forms and strengths

2 evidence topics · 2 sources

Investigational oral tablet

“Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food” (opens the source at this quote in a new tab)

MedChemExpress research-reagent safety data sheet

Field	Quoted information
Product name	“Saroglitazar (magnesium)”
Catalog number	“HY-19937A”
CAS number	“1639792-20-3”
Identified uses	“Laboratory chemicals, manufacture of substances.”

Zydus finished-product safety data sheet

No evidence found.